Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 41
Filter
1.
Oncogene ; 36(41): 5734-5744, 2017 10 12.
Article in English | MEDLINE | ID: mdl-28581517

ABSTRACT

With very similar 3D structures, the widely expressed ß-arrestin isoforms 1 and 2 play at times identical, distinct or even opposing roles in regulating various aspects of G protein-coupled receptors (GPCR) expression and signalling. Recent evidence recognizes the ß-arrestin system as a key regulator of not only GPCRs, but also receptor tyrosine kinases, including the highly cancer relevant insulin-like growth factor type 1 receptor (IGF-1R). Binding of ß-arrestin1 to IGF-1R leads to ligand-dependent degradation of the receptor and generates additional MAPK/ERK signalling, protecting cancer cells against anti-IGF-1R therapy. Because the interplay between ß-arrestin isoforms governs the biological effects for most GPCRs, as yet unexplored for the IGF-1R, we sought to investigate specifically the regulatory roles of the ß-arrestin2 isoform on expression and function of the IGF-1R. Results from controlled expression of either ß-arrestin isoform demonstrate that ß-arrestin2 acts in an opposite manner to ß-arrestin1 by promoting degradation of an unstimulated IGF-1R, but protecting the receptor against agonist-induced degradation. Although both isoforms co-immunoprecipitate with IGF-1R, the ligand-occupied receptor has greater affinity for ß-arrestin1; this association lasts longer, sustains MAPK/ERK signalling and mitigates p53 activation. Conversely, ß-arrestin2 has greater affinity for the ligand-unoccupied receptor; this interaction is transient, triggers receptor ubiquitination and degradation without signalling activation, and leads to a lack of responsiveness to IGF-1, cell cycle arrest and decreased viability of cancer cells. This study reveals contrasting abilities of IGF-1R to interact with each ß-arrestin isoform, depending on the presence of the ligand and demonstrates the antagonism between the two ß-arrestin isoforms in controlling IGF-1R expression and function, which could be developed into a practical anti-IGF-1R strategy for cancer therapy.


Subject(s)
Neoplasms/genetics , Receptor, IGF Type 1/genetics , beta-Arrestins/genetics , Animals , Gene Expression Regulation, Neoplastic , HEK293 Cells , Humans , Mice , Neoplasms/pathology , Phosphorylation , Protein Binding , Protein Isoforms/genetics , Protein Isoforms/metabolism , Proteolysis , Receptor, IGF Type 1/metabolism , Signal Transduction/genetics , Tumor Suppressor Protein p53/genetics , beta-Arrestins/metabolism
2.
J Thromb Haemost ; 6(9): 1542-9, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18624979

ABSTRACT

BACKGROUND: Factor Xa (FXa), a key serine protease that converts prothrombin to thrombin in the coagulation cascade, is a promising target enzyme for the prophylaxis and treatment of thromboembolic diseases. DU-176b is a novel antithrombotic agent that directly inhibits FXa activity. OBJECTIVE: To evaluate the in vitro pharmacological profiles and in vivo effects of DU-176b in animal models of thrombosis and bleeding. METHODS: In vitro, FXa inhibition, specificity and anticoagulant activities were examined. Oral absorption was studied in rats and cynomolgus monkeys. In vivo effects were studied in rat and rabbit models of venous thrombosis and tail bleeding. RESULTS: DU-176b inhibited FXa with Ki values of 0.561 nm for free FXa, 2.98 nm for prothrombinase, and exhibited >10 000-fold selectivity for FXa. In human plasma, DU-176b doubled prothrombin time and activated partial thromboplastin time at concentrations of 0.256 and 0.508 microm, respectively. DU-176b did not impair platelet aggregation by ADP, collagen or U46619. DU-176b was highly absorbed in rats and monkeys, as demonstrated by more potent anti-Xa activity and higher drug concentration in plasma following oral administration than a prototype FXa inhibitor, DX-9065a. In vivo, DU-176b dose-dependently inhibited thrombus formation in rat and rabbit thrombosis models, although bleeding time in rats was not significantly prolonged at an antithrombotic dose. CONCLUSIONS: DU-176b is a more potent and selective FXa inhibitor with high oral bioavailability compared with its prototype, DX-9065a. DU-176b represents a promising new anticoagulant for the prophylaxis and treatment of thromboembolic diseases.


Subject(s)
Factor Xa Inhibitors , Pyridines/pharmacology , Serine Proteinase Inhibitors/pharmacology , Thiazoles/pharmacology , Administration, Oral , Animals , Area Under Curve , Blood Coagulation/drug effects , Female , Macaca fascicularis , Male , Platelet Aggregation/drug effects , Pyridines/administration & dosage , Pyridines/pharmacokinetics , Rats , Rats, Wistar , Serine Proteinase Inhibitors/administration & dosage , Serine Proteinase Inhibitors/pharmacokinetics , Thiazoles/administration & dosage , Thiazoles/pharmacokinetics
3.
Br J Anaesth ; 89(2): 301-5, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12378671

ABSTRACT

BACKGROUND: There is still a possibility that mild hypothermic therapy may be useful as a neuroprotective tool during the intraoperative period, although the mechanism of cerebral protection by mild hypothermia is not well understood. We hypothesized that mild hypothermia may be protective against cerebral ischaemia by inhibiting post-ischaemia apoptosis. In this study, we used serum-deprived PC12 cells as the neuronal apoptotic model and examined the direct effects of mild and moderate hypothermia. METHODS: Apoptosis was induced by depriving the cell culture medium of serum, which is one of the most representative methods to induce apoptosis, but not necrosis, in PC12 cells. Effects of mild (35 and 33 degrees C) and moderate (31 and 29 degrees C) hypothermia on apoptosis were evaluated. Cytotoxicity (lactate dehydrogenase leakage) and the percentage of apoptotic cells (calculated by flow cytometry with propidium iodide) were evaluated 4 days after induction of apoptosis. As a control, cells without induction of apoptosis were incubated under the same conditions as the apoptosis group. RESULTS: Without induction at 37 degrees C, cytotoxicity and the percentage of apoptotic cells were over 60 and 90%, respectively. At each temperature examined below 35 degrees C, significant decreases in cytotoxicity and the percentage of apoptotic cells were observed. Mean cytotoxicity at 31 and 29 degrees C was 50.2 (SD 4.2)% and 47.9 (4.4)%, respectively. The percentage of apoptotic cells at 31 and 29 degrees C was 42.5 (7.4)% and 36.5 (7.3)%, respectively. In the control group, cytotoxicity and the percentage of apoptotic cells were significantly higher at 29 degrees C than at 37 degrees C. CONCLUSIONS: Mild and moderate hypothermia (29-35 degrees C) inhibited apoptosis, although hypothermia below 30 degrees C may induce apoptosis in intact cells.


Subject(s)
Apoptosis/physiology , Brain Ischemia/prevention & control , Hypothermia, Induced/methods , Animals , Brain Ischemia/pathology , Brain Ischemia/physiopathology , Flow Cytometry , L-Lactate Dehydrogenase/metabolism , PC12 Cells , Rats
4.
Cardiovasc Res ; 52(2): 314-20, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11684080

ABSTRACT

OBJECTIVES: Natural angiogenesis has been shown to be impaired in spontaneously hypertensive rats (SHR). The purpose of this study was to determine whether pathological angiogenesis in the setting of tissue ischemia is also impaired in SHR, and to what extent it is modified by angiotensin-converting enzyme (ACE) inhibition. METHODS: Ischemia was induced in the hindlimb of SHR by excision of the femoral artery, after which the animals were randomly assigned to receive low-dose perindopril (sub-antihypertensive, 0.2 mg/kg/day), high-dose perindopril (antihypertensive, 2.0 mg/kg/day), or vehicle for 3 weeks. Wistar-Kyoto rats (WKY) with femoral artery excision served as a control group. RESULTS: Tissue ACE activity in SHR was significantly increased compared to WKY (49.4+/-6.2 vs. 34.0+/-14.2 IU/mg, P<0.01). Administration of perindopril significantly reduced ACE activity in SHR (low dose: 12.4+/-2.3; high dose: 11.0+/-2.1 IU/mg, P<0.005). Angiogenesis of the ischemic limb muscles was significantly impaired at 4 weeks in SHR versus WKY as indicated by the lower capillary density in the former (364.5+/-43.0 vs. 463.8+/-63.0/mm(2), P<0.05) as well as the reduced hindlimb perfusion assessed by laser Doppler imaging (0.86+/-0.08 vs. 1.03+/-0.09, P<0.05). Administration of perindopril significantly augmented both the capillary density (low dose: 494.3+/-69.8; high dose: 543.9+/-76.9/mm(2), P<0.005) and the limb perfusion (low dose: 1.06+/-0.15; high dose: 1.05+/-0.12, P<0.05) of the ischemic limb in SHR. CONCLUSIONS: These findings indicate that pathological angiogenesis in the setting of tissue ischemia is impaired in SHR compared with WKY, and that this impairment can be reversed by ACE inhibition. The angiogenic properties of an ACE inhibitor may benefit patients with essential hypertension presenting with lower limb vascular insufficiency.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Hypertension/drug therapy , Ischemia/drug therapy , Perindopril/therapeutic use , Analysis of Variance , Animals , Capillaries/pathology , Hindlimb/blood supply , Hypertension/enzymology , Hypertension/pathology , Ischemia/enzymology , Ischemia/pathology , Male , Models, Animal , Muscle, Skeletal/enzymology , Peptidyl-Dipeptidase A/metabolism , Rats , Rats, Inbred SHR , Rats, Inbred WKY , Regional Blood Flow/drug effects
6.
Crit Care Med ; 28(6): 1899-904, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10890639

ABSTRACT

OBJECTIVE: Previous reports have demonstrated that barbiturates have a protective effect against cerebral ischemia, although the mechanisms are incompletely understood. Recently, it has been suggested that apoptosis is involved in ischemic neuronal death. This study examined the effect of pentobarbital on neuronal apoptosis. DESIGN: Randomized, controlled, prospective study. SETTING: University research laboratory. SUBJECTS: PC12 cells derived from rat pheochromocytoma as a model of neuronal tissue. INTERVENTIONS: Apoptosis was induced by depriving serum from the cell culture medium. Effect of pentobarbital (0.5, 5, 50 microg/mL) was evaluated. MEASUREMENTS AND MAIN RESULTS: First, electrophoresis of DNA and fluorescence microscopic examination were performed to ascertain whether apoptosis was really induced after serum deprivation in our cells. Second, the effect of pentobarbital on cytotoxicity (evaluated by a leakage assay of lactic dehydrogenase) was evaluated. Third, the percentage of apoptotic cells was calculated by measuring cellular DNA content with flow cytometry. Calculation of the percentage of apoptotic cells was based on cumulative frequency curves of the appropriate DNA histograms. DNA electrophoresis exhibited a typical ladder pattern from the first day after the induction of apoptosis. The cells with chromatin condensation and/or fragmentation increased day by day after depriving serum in fluorescence microscopic examination. Four days after the induction of apoptosis, cytotoxicity without pentobarbital was 53.9 +/- 24.3% (mean +/- SD). Pentobarbital significantly inhibited cell death in a dose-dependent fashion. The percentage of apoptotic cells without pentobarbital was 94.9 +/- 6.3% 4 days after the induction of apoptosis. The treatment with 50 microg/mL pentobarbital significantly decreased the percentage of apoptotic cells to 61.8 +/- 21.3%. CONCLUSIONS: Our data indicate that pentobarbital inhibits apoptosis induced by serum deprivation in PC12 cells.


Subject(s)
Apoptosis/drug effects , Hypnotics and Sedatives/pharmacology , Neurons/drug effects , Neurons/physiology , Pentobarbital/pharmacology , Cells, Cultured , Humans
7.
Anesth Analg ; 91(2): 347-52, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10910846

ABSTRACT

UNLABELLED: Calcium channel blockers are effective in stabilizing systemic hemodynamics during tracheal extubation. However, they may increase cerebral blood flow (CBF) during tracheal extubation because of cerebral vasodilation, even if systemic arterial blood pressure decreases. In this study, we observed changes in cerebral oxygenation during tracheal extubation by using near-infrared spectroscopy and evaluated the effect of nicardipine and diltiazem on the resultant changes. We studied 45 women undergoing elective gynecologic surgery. After surgery, the patients were randomly allocated to three groups (n = 15 each): saline (control), 0.02 mg/kg nicardipine, and 0.2 mg/kg diltiazem. After 2 min, we started to aspirate secretions for 2 min and then, extubated the trachea. Changes in cerebral oxygenated hemoglobin (HbO(2)) and deoxygenated hemoglobin were measured during the extubation procedure for 9 min after drug treatment. Systemic hemodynamics, including mean arterial blood pressure, heart rate, end-tidal CO(2), end-tidal sevoflurane concentration, and peripheral arterial oxygen saturation were also monitored. During extubation, HbO(2) increased significantly, presumably caused by the increase in CBF. Changes in deoxygenated hemoglobin were minimal. Compared with the control, nicardipine and diltiazem significantly inhibited the increase in mean arterial blood pressure. On the contrary, they significantly enhanced the increase in HbO(2). In conclusion, calcium channel blockers may increase CBF during extubation, even if these drugs stabilize systemic hemodynamics. IMPLICATIONS: This study is a preliminary report evaluating the changes in cerebral oxygenation during the tracheal extubation. Cerebral oxygenated hemoglobin increased significantly, presumably caused by the increase in cerebral blood flow during extubation. In addition, these changes were enhanced by calcium channel blockers.


Subject(s)
Brain/metabolism , Calcium Channel Blockers/pharmacology , Cerebrovascular Circulation/drug effects , Diltiazem/pharmacology , Intubation, Intratracheal , Nicardipine/pharmacology , Oxyhemoglobins/analysis , Blood Pressure/drug effects , Double-Blind Method , Female , Gynecologic Surgical Procedures , Heart Rate/drug effects , Humans , Oxygen/blood , Spectroscopy, Near-Infrared , Vasodilation/drug effects
8.
J Smooth Muscle Res ; 36(1): 33-46, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10830476

ABSTRACT

Endothelium-dependent relaxation of aorta and carotid artery from stroke-prone spontaneously hypertensive rats (SHRSP) and the effect of chronic treatment of SHRSP with perindopril, an angiotensin converting enzyme inhibitor, on endothelium-dependent relaxation were studied. Endothelium-dependent relaxation was induced by acetylcholine (ACh) in preparations of SHRSP and normotensive Wistar Kyoto rats (WKY) precontracted with noradrenaline. The ACh-induced relaxation in both preparations was abolished by L-nitroarginine. The ACh-induced relaxation was impaired in preparations from SHRSP and contraction was observed at high concentrations of ACh. In the presence of indomethacin, impairment of endothelium-dependent relaxation in SHRSP was minimized and the contraction was inhibited. The relaxation with sodium nitroprusside did not differ between the preparations from WKY and SHRSP. Treatment of SHRSP with perindopril (2 mg/kg/day) for 6 weeks decreased systolic blood pressure and improved the ACh-induced relaxation of aorta and carotid artery. The treatment inhibited the contraction by higher concentrations of ACh in the presence of L-nitroarginine. These results indicate that the impairment of endothelium-dependent relaxation in aorta and carotid artery of SHRSP may be caused by the reduced availability of nitric oxide. The perindopril-treatment may prevent these changes in SHRSP.


Subject(s)
Antihypertensive Agents/pharmacology , Aorta/physiology , Carotid Arteries/physiology , Endothelium, Vascular/drug effects , Perindopril/pharmacology , Vasodilation/physiology , Acetylcholine/pharmacology , Animals , Aorta/drug effects , Blood Pressure , Body Weight , Carotid Arteries/drug effects , Dose-Response Relationship, Drug , Male , Nitroprusside/pharmacology , Norepinephrine/pharmacology , Rats , Rats, Inbred SHR , Rats, Inbred WKY , Vasoconstrictor Agents/pharmacology , Vasodilation/drug effects , Vasodilator Agents/pharmacology
9.
Jpn J Antibiot ; 53(3): 157-70, 2000 Mar.
Article in Japanese | MEDLINE | ID: mdl-10834147

ABSTRACT

During October and December of each year of from 1994 to 1996, 3,849 strains of 10 species of bacteria were isolated from clinical materials in 21 institutions nationwide. The minimum inhibitory concentrations (MICs) for these bacteria of four carbapenems (imipenem [IPM], panipenem [PAPM], meropenem [MEPM], and biapenem [BIPM]) and other representative antibacterial agents were measured to investigate annual changes in antibacterial activity. Carbapenems showed potent activity against methicillin-sensitive S. aureus (MSSA), S. pneumoniae, E. faecalis, H. influenzae, E. coli, K. pneumoniae, E. cloacae, S. marcescens, and the B. fragilis group, with the activity being stable. However, these drugs showed weak activity against methicillin-resistant S. aureus (MRSA) and P. aeruginosa. The antibacterial activity (MIC90) against the tested organisms generally remained stable. Particularly, there was annual improvement of the MIC90 values of IPM and BIPM for S. pneumoniae, as well as the values of IPM and PAPM for H. influenzae, and those of IPM, PAPM, and BIPM for S. marcescens. On the other hand, the activity of carbapenems (including IPM) against MRSA was not necessarily strong, but there was annual improvement of MIC90 values.


Subject(s)
Bacteria/drug effects , Carbapenems/pharmacology , Bacteria/isolation & purification , Drug Resistance, Microbial , Humans , Imipenem/pharmacology , Japan , Meropenem , Multicenter Studies as Topic , Thienamycins/pharmacology , Time Factors
10.
Clin Exp Hypertens ; 21(7): 1223-38, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10513838

ABSTRACT

The present study was designed to evaluate trough-to-peak ratio (T/P) of ACE inhibitors in spontaneously hypertensive rats (SHR) by a continuous monitoring of ambulatory blood pressure for 24 hours with a biotelemetric system. Blood pressure was recorded uninterruptedly with a battery-operated transmitter connected to a sensor catheter. Perindopril (3 mg/kg), trandolapril (1 mg/kg), quinapril (10 mg/kg) and enalapril (6 mg/kg) were given once a day for 7 days. On the first day of the treatment these ACE inhibitors equally decreased blood pressure by 20 mmHg at each peak. The peak and trough blood pressure decreased steadily until day 4, and then they were constant until the end of experiment (day 7). T/P for each inhibitor also increased until day 4, and the ratios in systolic blood pressure at the end of experiments (day 7) were as follows, perindopril: 0.63, trandolapril: 0.62, quinapril: 0.41, enalapril: 0.27. The T/P of perindopril was significantly higher than that of enalapril. The results of the present studies testing four ACE inhibitors are well consistent with those in clinical trials. Thus, the measurement of T/P in SHR would provide a meaningful information for the evaluation of antihypertensive agents like ACE inhibitors.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/pharmacology , Blood Pressure/physiology , Circadian Rhythm/physiology , Hypertension/physiopathology , Locomotion/physiology , Perindopril/pharmacology , Tetrahydroisoquinolines , Animals , Blood Pressure/drug effects , Blood Pressure Monitoring, Ambulatory/methods , Circadian Rhythm/drug effects , Enalapril/pharmacology , Heart Rate/drug effects , Hypertension/drug therapy , Indoles/pharmacology , Isoquinolines/pharmacology , Locomotion/drug effects , Male , Quinapril , Random Allocation , Rats , Rats, Inbred SHR , Telemetry
11.
Chem Pharm Bull (Tokyo) ; 47(7): 915-8, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10434393

ABSTRACT

Two new anti-allergic compounds, torososide B and torosachrysone 8-O-6"-malonyl gentiobioside were isolated from the seeds of Cassia torosa Cav., and their structures were established as physcion 8-O-beta-D-glucopyranosyl-(1-->6)-beta-D-glucopyranosyl- (1-->3)-beta-D-glucopyranosyl-(1-->6)-beta-D-glucopyranoside and torosachrysone 8-O-beta-D-glucopyranosyl-(1-->6)-6-malonyl beta-D-glucopyranoside on the basis of spectral and chemical evidence. Torososide B and torosachrysone 8-O-6"-malonyl gentiobioside were found to inhibit the release of leucotrienes from rat peritoneal mast cells induced by calcium ionophore A 23187.


Subject(s)
Anti-Allergic Agents/chemistry , Cassia/chemistry , Disaccharides/chemistry , Leukotriene Antagonists/chemistry , Oligosaccharides/chemistry , Plants, Medicinal , Animals , Anti-Allergic Agents/pharmacology , Carbohydrate Sequence , Depression, Chemical , Disaccharides/pharmacology , In Vitro Techniques , Leukotriene Antagonists/isolation & purification , Leukotriene Antagonists/pharmacology , Leukotrienes/metabolism , Magnetic Resonance Spectroscopy , Male , Mast Cells/drug effects , Mast Cells/metabolism , Molecular Sequence Data , Oligosaccharides/pharmacology , Rats , Rats, Wistar , Structure-Activity Relationship
12.
Jpn J Antibiot ; 52(4): 279-91, 1999 Apr.
Article in Japanese | MEDLINE | ID: mdl-10396685

ABSTRACT

Research groups were formed in 21 institutions nationwide to investigate carbapenem resistance. The activities of various antibacterial agents, principally carbapenems, were tested against clinical isolates collected from these institutions. The broth microdilution method was used to determine the minimum inhibitory concentrations (MIC) of 17 antibacterial agents for 1,241 strains of 11 bacterial species isolated at all institutions between October and December 1996. The results were as follows: Carbapenems exhibited strong antibacterial activities against MSSA and Streptococcus pneumoniae and showed low activities against MRSA. Their activities against Enterococcus faecalis were comparable to that of ampicillin and piperacillin. The carbapenems showed high activities against Haemophilis influenzae, Escherichia coli, Klebsiella pneumoniae. Enterobacter cloacae. Serratia marcescens and Bacteroides fragilis group. Their activities were greater than that exhibited by other beta-lactam antibacterial agents, but some resistant strains of Serratia marcescens were detected. The antibacterial activity of carbapenems against Pseudomonas aeruginosa was comparable to that of CAZ, and there were some resistant strains.


Subject(s)
Carbapenems/pharmacology , Gram-Negative Bacteria/drug effects , Gram-Positive Cocci/drug effects , Drug Resistance, Microbial , Gram-Negative Bacteria/isolation & purification , Gram-Positive Cocci/isolation & purification , Humans , Imipenem/pharmacology , Meropenem , Microbial Sensitivity Tests/methods , Thienamycins/pharmacology , Time Factors
13.
Biol Pharm Bull ; 22(6): 647-53, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10408242

ABSTRACT

An extract of Melastoma dodecandrum LOUR. with 80% aqueous acetone (MDL) inhibited nitric oxide (NO) production by a murine macrophage-like cell line, RAW264.7, activated with lipopolysaccharide (LPS) and recombinant mouse interferon-gamma (IFN-gamma). On further fractionation of the extract, the majority of the inhibitory activity was recovered in the 50% methanol extracts, which contained hydrolyzable tannins. Among the latter, casuarinin, casuarictin, pedunclagin and nobotannin B exhibited strong inhibitory activities toward NO production, with ID50 values between 2.0 and 5.1 microM. Both MDL and the purified tannins significantly reduced the induction of the inducible nitric oxide synthase (iNOS) protein in the course of macrophage activation with LPS and IFN-gamma. In addition, the NO production by macrophages preactivated with LPS and IFN-gamma for 16 h was also inhibited by these tannins, with IC50 values around 30-130 microM, but not by MDL. These results suggest that MDL has the pharmacological ability to suppress NO production by activated macrophages and that the hydrolyzable tannins have major inhibitory activities.


Subject(s)
Hydrolyzable Tannins/pharmacology , Interferon-gamma/pharmacology , Lipopolysaccharides/pharmacology , Macrophages/metabolism , Nitric Oxide/biosynthesis , Plants, Medicinal , Animals , Cell Line , Hydrolysis , Mice , Nitric Oxide Synthase/antagonists & inhibitors , Nitric Oxide Synthase Type II , Plant Extracts/pharmacology
14.
J Mol Cell Cardiol ; 31(6): 1261-8, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10371700

ABSTRACT

Beta-adrenergic receptor kinase 1 (beta ARK1) participates in the desensitization of beta-adrenergic receptors by uncoupling the signal transduction. The present study was designed to examine whether neurohumoral increase is crucial for the activation of beta ARK1 in heart failure. Four weeks after the ligation of rat coronary artery, LV dP/d t max was reduced, cardiac response to isoproterenol was impaired, and ratio of right ventricular weight to body weight, an index of cardiac hypertrophy, was increased. At the same time, beta ARK1 expression and activity were augmented in the hypertrophied hearts. In addition, plasma norepinephrine content was enhanced in accordance with cardiac hypertrophy, cardiac beta ARK1 expression, LV dP/d t max, and LVEDP. These results of the present study suggest that beta ARK1 is augmented in concert with circulating norepinephrine level and that beta ARK1 may account for, at least in part, the cardiac dysfunction in rat with myocardial infarction.


Subject(s)
Cyclic AMP-Dependent Protein Kinases/metabolism , Heart Failure/enzymology , Myocardium/enzymology , Animals , Coronary Vessels/surgery , Enzyme Induction , Ligation , Male , Norepinephrine/blood , Organ Size , Rats , Rats, Sprague-Dawley , beta-Adrenergic Receptor Kinases
15.
Chem Pharm Bull (Tokyo) ; 46(10): 1650-2, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9810700

ABSTRACT

Two new naphthopyrones, cassiasides B2 (1) and C2 (2), were isolated from the seeds (Cassiae Semen) of Cassia obtusifolia L. The structures of the two new compounds 1 and 2 were established as rubrofusarin 6-O-beta-D- glucopyranosyl-(1-->6)-O-beta-D-glucopyranosyl-(1-->3)-O-beta-D- glucopyranosyl-(1-->6)-O-beta-D-glucopyranoside and toralactone 9-O-beta-D-glucopyranosyl-(1-->6)-O-beta-D-glucopyranosyl- (1-->3)-O-beta-D-glucopyranosyl-(1-->6)-O-beta-D-glucopyranoside, respectively, on the basis of spectral and chemical evidence. Compound 2 was found to inhibit the histamine release from rat peritoneal exudate mast cells induced by antigen-antibody reaction.


Subject(s)
Anti-Allergic Agents/analysis , Cassia/chemistry , Histamine Release/drug effects , Oligosaccharides/pharmacology , Plants, Medicinal , Pyrones/pharmacology , Animals , Antigen-Antibody Reactions , Carbohydrate Sequence , Exudates and Transudates/cytology , Exudates and Transudates/drug effects , Exudates and Transudates/metabolism , In Vitro Techniques , Magnetic Resonance Spectroscopy , Male , Mast Cells/drug effects , Molecular Sequence Data , Oligosaccharides/isolation & purification , Pyrones/isolation & purification , Rats , Seeds/chemistry
16.
Jpn J Antibiot ; 51(2): 47-68, 1998 Feb.
Article in Japanese | MEDLINE | ID: mdl-9575436

ABSTRACT

Research groups were formed in 21 institutions nationwide to investigate carbapenem resistance. The activities of various antibacterial agents, principally carbapenems were tested against clinical isolates collected from these institutions. The broth microdilution method was used to determine the minimum inhibitory concentrations (MIC) of 17 antibacterial agents for 1,282 strains of 11 bacterial species isolated at all institutions between October and December 1995. The results were as follows: 1. Carbapenems exhibited strong antibacterial activities against MSSA and Streptococcus pneumoniae. Their activities against Enterococcus faecalis were comparable to that of ABPC. Carbapenems showed low activities against MRSA. 2. OFLX exhibited the greatest antibacterial activity against Haemophilus influenzae, followed by MEPM. The antibacterial activities of the other carbapenems were comparable to those of FMOX and CTM. 3. The carbapenems showed high activities against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, and Bacteroides fragilis group. Their activities were greater than that exhibited by other beta-lactam antibacterial agents. The carbapenems also exhibited greater antibacterial activities against Serratia marcescens than the other beta-lactam antibacterial agents, but some resistant strains were detected. 4. The antibacterial activities of carbapenems against Pseudomonas aeruginosa were comparable to those of CAZ, AZT, AMK.


Subject(s)
Carbapenems/pharmacology , Staphylococcus aureus/drug effects , Streptococcus pneumoniae/drug effects , Drug Resistance, Microbial , Enterococcus faecalis/drug effects , Enterococcus faecalis/isolation & purification , Escherichia coli/drug effects , Escherichia coli/isolation & purification , Humans , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/isolation & purification , Serratia marcescens/drug effects , Serratia marcescens/isolation & purification , Staphylococcus aureus/isolation & purification , Streptococcus pneumoniae/isolation & purification
17.
J Biol Chem ; 273(8): 4635-41, 1998 Feb 20.
Article in English | MEDLINE | ID: mdl-9468522

ABSTRACT

To identify the binding domain of a new Ca2+ antagonist semotiadil on L-type Ca2+ channels from skeletal muscle, photolabeling was carried out by using an azidophenyl derivative of [3H]semotiadil. Photoincorporation was observed in several polypeptides of membrane triad preparations; the only specific photoincorporation was in the alpha1 subunit of the Ca2+ channel. After solubilization and purification, the photolabeled alpha1 subunit was subjected to proteolytic and CNBr cleavage followed by antibody mapping. Specific labeling was associated solely with the region of transmembrane segment S6 in repeat IV. Quantitative immunoprecipitation was found in the tryptic and the Lys-C/Glu-C fragments of 6.6 and 6.1 kDa, respectively. Further CNBr cleavage of the Lys-C digests produced two smaller fragments of 3.4 and 1.8 kDa that were included in the tryptic and Lys-C/Glu-C fragments. The smallest labeled fragments were: Tyr1350-Met1366 and Leu1367-Met1381 containing IVS6, a possible pore-forming region. The data suggest that semotiadil binds to a region that is overlapped with but not identical to those for phenylalkylamines, dihydropyridines and benzothiazepines. The present study also provides evidence that region IV represents an important component of a binding pocket for Ca2+ antagonists.


Subject(s)
Calcium Channel Blockers/metabolism , Thiazoles/metabolism , Animals , Azides/metabolism , Binding Sites , Calcium Channel Blockers/chemistry , Cell Membrane/metabolism , Cyanogen Bromide/chemistry , Metalloendopeptidases/chemistry , Muscle, Skeletal/metabolism , Peptide Mapping , Photoaffinity Labels , Rabbits , Thiazines/metabolism , Thiazoles/chemistry , Tritium , Trypsin/chemistry
18.
FEBS Lett ; 441(1): 83-7, 1998 Dec 11.
Article in English | MEDLINE | ID: mdl-9877170

ABSTRACT

We have previously identified the binding region of a new Ca2+ antagonist semotiadil in the skeletal muscle Ca2+ channel. To the same semotiadil derivatives, the cardiac counterpart showed distinct and different binding characteristics: semotiadil and its photoaffinity analog D51-4700 inhibited [3H]PN200-110 binding to cardiac membrane preparations with IC50 values of 13-20 microM, which are 10 times higher than those in skeletal muscle. Hill slopes of the binding inhibition were 0.94-1.0 for the cardiac channels compared to 0.63-0.67 for the skeletal muscle channels. A possible explanation for the difference is that the semotiadil binding site is differently conferred in cardiac and skeletal muscle Ca2+ channels. To reveal this within the primary structure, photoaffinity labeling of cardiac membranes was employed. [3H]D51-4700 was photo-incorporated in several polypeptides but only the alpha1 subunit of the Ca2+ channel was photolabeled in a specific manner. Antibody mapping of the [3H]D51-4700-labeled alpha1 subunit with several anti-peptide antibodies revealed that the labeled site was located solely in a peptide fragment between Cys1461 and Lys1529. This region encompasses the labeled site of skeletal muscle, but contains several non-identical amino acid residues, which may participate in expressing different binding characteristics between the two muscle type Ca2+ channels.


Subject(s)
Calcium Channel Blockers/metabolism , Calcium Channels/chemistry , Calcium Channels/metabolism , Muscle, Skeletal/metabolism , Myocardium/metabolism , Thiazoles/metabolism , Amino Acid Sequence , Animals , Azides/pharmacology , Binding Sites , Binding, Competitive , Calcium Channel Blockers/pharmacology , Cell Membrane/metabolism , Isradipine/pharmacokinetics , Kinetics , Macromolecular Substances , Molecular Sequence Data , Peptide Fragments/chemistry , Photoaffinity Labels , Photochemistry , Swine , Thiazines/pharmacology , Thiazoles/pharmacology
19.
Biochem Biophys Res Commun ; 239(2): 548-51, 1997 Oct 20.
Article in English | MEDLINE | ID: mdl-9344867

ABSTRACT

Asp278 of beta-adrenergic receptor kinase 1 (betaARK1) was suggested to play a key role in substrate recognition of beta2-adrenergic receptors in our previous study, in which a three-dimensional model of betaARK1 was studied in comparison with a crystal structure of PKA-PKI5-24 complex. In the present study, to confirm the molecular recognition mechanism at Asp278 of betaARK1, two mutants of betaARK1, D278R and D278A, were designed based on molecular modeling studies and produced by Sf-9 cells. As predicted by the molecular modeling study, the mutants showed no kinase activities while wild type betaARK1 phosphorylated beta2-adrenergic receptors in a concentration-dependent manner. These results strongly suggest the involvement of Asp278 in substrate recognition by betaARK1. The results also suggest a high reliability of the three-dimensional model of betaARK1.


Subject(s)
Aspartic Acid/physiology , Cyclic AMP-Dependent Protein Kinases/metabolism , Alanine/genetics , Amino Acid Substitution/genetics , Arginine/genetics , Aspartic Acid/genetics , Conserved Sequence , Crystallography, X-Ray , Cyclic AMP-Dependent Protein Kinases/chemistry , Cyclic AMP-Dependent Protein Kinases/genetics , Humans , Models, Molecular , Mutagenesis, Site-Directed , Phosphorylation , Substrate Specificity , beta-Adrenergic Receptor Kinases
20.
Jpn J Antibiot ; 50(8): 683-703, 1997 Aug.
Article in Japanese | MEDLINE | ID: mdl-9339395

ABSTRACT

Research groups were formed in 20 institutions nationwide to investigate carbapenem resistance of clinical isolates. Activities of various antibacterial agents, principally carbapenems, were tested against clinical isolates collected from these institutions. The broth microdilution method was used to determine the minimum inhibitory concentrations (MICs) of 17 antibacterial agents for 1,326 strains of 11 bacterial species isolated at the institutions between October and December 1994. The results are as follows: 1. Carbapenems exhibited strong antibacterial activities against MSSA and Streptococcus pneumoniae. Their activities against Enterococcus faecalis were comparable to that of ABPC. Carbapenems showed low activities against MRSA. 2. OFLX exhibited the greatest antibacterial activity against Haemophilus influenzae, followed by MEPM. Antibacterial activities of the other carbapenems were comparable to those of FMOX, CTM, and ABPC. 3. The carbapenems showed high activities against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, and Bacteroides fragilis group. Their activities were greater than those exhibited by other beta-lactam antibacterial agents. The carbapenems also exhibited stronger antibacterial activities against Serratia marcescens than the other beta-lactam antibacterial agents, but some resistant strains were detected. 4. The antibacterial activities of carbapenems against Pseudomonas aeruginosa were comparable to those of CAZ, AZT, AMK.


Subject(s)
Bacteria/drug effects , Carbapenems/pharmacology , Thienamycins/pharmacology , 4-Quinolones , Aminoglycosides , Anti-Bacterial Agents/pharmacology , Anti-Infective Agents/pharmacology , Cephalosporins/pharmacology , Drug Resistance, Microbial , Gram-Negative Bacteria/drug effects , Gram-Positive Cocci/drug effects , Haemophilus influenzae/drug effects , Humans , Imipenem/pharmacology , Meropenem , Monobactams/pharmacology , Penicillins/pharmacology , Pseudomonas aeruginosa/drug effects , Serratia marcescens/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...